Moreover, the 36-month beta value for HUMA is 1.29. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for HUMA is 104.38M and currently, short sellers hold a 23.03% of that float. On February 21, 2025, HUMA’s average trading volume was 4.15M shares.
HUMA) stock’s latest price update
Humacyte Inc (NASDAQ: HUMA) has experienced a decline in its stock price by -3.10 compared to its previous closing price of 3.87. However, the company has seen a fall of -5.30% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-20 that PHILADELPHIA, PA / ACCESS Newswire / February 20, 2025 / Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. (“Humacyte”) (NASDAQ:HUMA) breached their fiduciary duties by failing to manage Humacyte in an acceptable manner and whether Humacyte and its shareholders were harmed as a result.
HUMA’s Market Performance
Humacyte Inc (HUMA) has experienced a -5.30% fall in stock performance for the past week, with a -17.76% drop in the past month, and a -22.44% drop in the past quarter. The volatility ratio for the week is 5.56%, and the volatility levels for the past 30 days are at 5.52% for HUMA.. The simple moving average for the past 20 days is -11.64% for HUMA’s stock, with a -33.57% simple moving average for the past 200 days.
Analysts’ Opinion of HUMA
Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 20, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $6. The rating they have provided for HUMA stocks is “Buy” according to the report published on December 11th, 2023.
Piper Sandler gave a rating of “Neutral” to HUMA, setting the target price at $3.50 in the report published on August 14th of the previous year.
HUMA Trading at -15.11% from the 50-Day Moving Average
After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.39% of loss for the given period.
Volatility was left at 5.52%, however, over the last 30 days, the volatility rate increased by 5.56%, as shares sank -18.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.48% lower at present.
During the last 5 trading sessions, HUMA fell by -5.30%, which changed the moving average for the period of 200-days by -14.77% in comparison to the 20-day moving average, which settled at $4.24. In addition, Humacyte Inc saw -25.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUMA starting from Constantino Michael T., who purchase 4,600 shares at the price of $4.39 back on Dec 04 ’24. After this action, Constantino Michael T. now owns 16,950 shares of Humacyte Inc, valued at $20,181 using the latest closing price.
Niklason Laura E, the President, CEO and Director of Humacyte Inc, purchase 1,797 shares at $4.44 during a trade that took place back on Nov 19 ’24, which means that Niklason Laura E is holding 243,851 shares at $7,979 based on the most recent closing price.
Stock Fundamentals for HUMA
Current profitability levels for the company are sitting at:
- -10.43 for the present operating margin
- 0.35 for the gross margin
The net margin for Humacyte Inc stands at -14.17. The total capital return value is set at -1.2. Equity return is now at value -850.81, with -115.74 for asset returns.
Based on Humacyte Inc (HUMA), the company’s capital structure generated -0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -5.25. The debt to equity ratio resting at -0.27. The interest coverage ratio of the stock is -13.24.
Currently, EBITDA for the company is -96.46 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 44.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.10.
Conclusion
To wrap up, the performance of Humacyte Inc (HUMA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
